Skip to content
2000
Volume 6, Issue 3
  • ISSN: 1871-5230
  • E-ISSN: 1875-614X

Abstract

Inhibition of the proinflammatory cytokine TNF-α has been shown to be an effective strategy for treating inflammatory dermatoses. Etanercept competitively inhibits the interaction of TNF, interrupting the proinflammatory cytokine cascade and preventing TNF mediated cellular responses. The success of etanercept in a wide range of dermatologic conditions especially in psoriasis gives a new hope in dermatological therapy field. This article reviews the pharmacokinetic properties, safety profile, administration route and efficacy in different dermatological conditions of etanercept.

Loading

Article metrics loading...

/content/journals/aiaamc/10.2174/187152307781368256
2007-08-01
2025-05-13
Loading full text...

Full text loading...

/content/journals/aiaamc/10.2174/187152307781368256
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test